Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Sensorion logo — Our mission: find solutions for hearing disorders

Sensorion

Our mission: find solutions for hearing disorders

Founded 2009 France France 85 employees Post-IPO Equity Total: $98.25M Biopharma, Biotechnology +2

General Information

Company Name Sensorion
Founded Year 2009
Location France France
Employees 85
Industries Biopharma, Biotechnology, Health Care +1
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Sensorion. To contact Sensorion, visit sensorion.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Sensorion compare?

A PDF of Sensorion and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Sensorion soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Sensorion

Sensorion is a clinical-stage biotechnology company founded in 2009, with a mission to find solutions for hearing disorders. The company's clinical-stage portfolio includes SENS-401 (Arazasetron), a Phase 2 product being studied in Cisplatin-Induced Ototoxicity (CIO) and in patients scheduled for cochlear implantation in collaboration with Cochlear Limited.

Sensorion has also formed a strategic partnership with Institut Pasteur focused on the genetics of hearing and has two gene therapy programs, OTOF-GT and GJB2-GT, targeting hereditary monogenic forms of deafness. These programs aim to address important hearing loss segments in adults and children.

The latest investment of €50.50M in Post-IPO Equity was secured on February 9, 2024, with participation from Sofinnova Partners, Invus, Redmile Group, and Aquilo Capital Management. Headquartered in France, Sensorion is advancing innovative therapies to restore, treat, and prevent hearing loss disorders within the healthcare and biopharma industries.

Business keywords: Clinical-stage development, Therapeutic solutions, Hearing disorders, Gene therapy, Monogenic deafness, Inner ear disorders, Vestibular deficits, Small molecule therapies, Ototoxicity, Cochlear implants, Partnership with Institut Pasteur, Genetics of hearing, Arazasetron, Phase 2 clinical studies

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity €50.50M 4
Sofinnova Partners Invus Redmile Group
Sofinnova Partners, Invus +2
09 Feb 2024
Post IPO Equity €35.00M 3
Sofinnova Partners Invus Redmile Group
Sofinnova Partners, Invus +1
03 Aug 2023
Post IPO Equity €8.00M 1
Crede CapitalGroup
Crede CapitalGroup
15 Jul 2015
Venture Round €4.00M 2
Inserm Transfert Initiative
Inserm Transfert Initiative, InnoBio Fund
21 Jan 2015
Venture Round €750.00K -
26 Apr 2012

Sensorion Alternatives & Competitors

View All Alternatives
Sensorion vs
Fennec Pharmaceuticals Inc
Fennec Pharmaceuticals Inc

Fiercely devoted to the fight against ototoxicity in pediatric cancer patients who receive cisplatin...

Post-IPO Debt
32 employees
Biopharma, Biotechnology
Compare Sensorion vs Fennec Pharmaceuticals Inc
Sensorion vs
Pharvaris
Pharvaris Switzerland

Pioneering science for patient choice

IPO
168 employees
Biotechnology, Health Care
Compare Sensorion vs Pharvaris
Sensorion vs
ImmunoMet Therapeutics, Inc.
ImmunoMet Therapeutics, Inc.

Targeting Metabolic Reprogramming in Fibrosis and Oncology

7 employees
Biopharma, Biotechnology
Also compare with: Sensorion vs Atsena Therapeutics Atsena Therapeutics Sensorion vs Decibel Therapeutics Decibel Therapeutics View all alternatives

FAQ About Sensorion

Our mission: find solutions for hearing disorders
Sensorion was founded in 2009.
Sensorion is headquartered in France.
Sensorion operates in Biopharma, Biotechnology, Health Care and Health and Wellness. Its work centres on Clinical-stage development, Therapeutic solutions, Hearing disorders and Gene therapy.
Sensorion has approximately 85 employees.
Sensorion has completed 5 funding rounds, raising a total of $98.25M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Sensorion include Fennec Pharmaceuticals Inc, Pharvaris, ImmunoMet Therapeutics, Inc., Atsena Therapeutics, Decibel Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Sensorion and Fennec Pharmaceuticals Inc are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Sensorion, https://bouncewatch.com/company/sensorion, updated 7 June 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes